This future of "never-ending variants & vaccines" for SARS-CoV-2 was always in the cards from the beginning. This virus was too infectious to go away on it's own. Unfortunately, few people saw it that way this past year. However, I see a less negative future than what you fear.
If we can get enough people vaccinated in the next two years (one year is too optimistic), the virus won't disappear, but it will be much less widespread. It will be suppressed but not eliminated. The variants we've seen so far can also be suppressed with edited vaccines directed against the variant spike proteins. Remember also that the vaccines we've seen so far are only the first efforts. Other vaccines are in the works. Some could be much better at controlling the virus.
This past year was the outbreak year for SARS-CoV-2. It ran amok in a population never previously exposed to it. Because of large numbers of infections – and the resulting very large amount of virus reproduction events – plenty of mutations emerged. Some of them became successful mutations. In the future, this virus (or it's mutated progeny) will still be around, but because of vaccination they won't infect such a large percentage of the population. With widespread vaccination, we'll see fewer new mutations because the infection rate will be lower.
At the risk of being a rosy-eyed optimist, I'll raise a purely theoretical idea. Evolution tells us the virus's future depends on being highly infectious, but less fatal to it's human hosts. This is what clearly happened with the Spanish Flu epidemic of 1918-19. In those first years, it also ran amok, killing millions world wide. But it also evolved. All of today's flu strains are direct decedents of that Spanish Flu virus – we have DNA sequence evidence to prove this. But the progeny of the Spanish Flu evolved to become a much smaller threat to the human population. I'd like to believe that SARS-CoV-2 will do the same. We can help tame it sooner by rapid and widespread vaccinations.
I hope you are right.
I ran across an interesting article on this topic. Killer T cells got some good press:
>>>It will be difficult to know from serum samples if or when a mutant has escaped a vaccine, partly because researchers do not know where to draw the line between an immune response that is protective against SARS-CoV-2 and one that is not. “We don’t know for sure exactly what kinds of immune responses or what antibody titers are truly necessary for clinical vaccine protection in humans,” says Barouch. When he and his colleagues transferred convalescent serum to macaques and challenged them with SARS-CoV-2, they found that relatively low antibody levels
protected the primates, but only if the serum contained adequate levels of CD8+ killer T cells.
The involvement of these T cells, which kill cells infected with virus, complicates the picture. Having more CD8+ T cells is linked to
milder COVID-19. So far, from his calculations, Sette says the T cells stimulated by vaccines or infection to an early lineage of SARS-CoV-2 should largely recognize the new variants. He studied
T cell responses in COVID-19 and found that an average person’s T cells recognize multiple parts of SARS-CoV-2—“at least 15 to 20 different pieces,” he says, including on the spike and several other proteins. For that reason, he concludes, “it is very unlikely that the virus could mutate to escape T cell recognition.”
Some vaccines are suspected to provoke a stronger T cell response than others do. Vector-based and mRNA vaccines, for example, mirror natural infection with SARS-CoV-2, forming the spike protein inside cells—a process that is thought to strongly activate killer T cells, says Barouch, whereas “protein-based and inactivated-virus vaccines generally don’t raise a strong CD8 T cell response.” Chemical adjuvants used in protein and inactivated-virus vaccines may promote killer T cells, says Sette, and side-by-side comparisons of T cell and antibodies have not been done yet between vaccines.<<<
Facing new variants of SARS-CoV-2, some vaccines may offer more robust protection or be more easily redesigned to target them.
www.the-scientist.com